




Phosphorus

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application. The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Section: 18. Medicines for endocrine disorders

		EMLc	ATC codes: V03AG05
Indication	Hypophosphataemic rickets	ICD11 code: 5C63.22	
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Oral > Other: 500 mg in sachet (elemental phosphorus) granules (EMLc) Oral > Solid > tablet: 250 mg (elemental phosphorus) (EMLc) ; 500 mg (elemental phosphorus) (EMLc) ; 500 mg (elemental phosphorus) (effervescent) (EMLc)		
EML status history	Application rejected in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Wikipedia	Phosphorus 		
DrugBank	Phosphorus 		

Summary of evidence and Expert Committee recommendations

The Expert Committee did not recommend the inclusion of phosphorus on the complementary list of the EMLc, for the treatment of hypophosphataemic rickets in children. The Committee noted evidence from small cohort studies which suggests that early introduction of treatment with phosphorus and vitamin D in children with hypophosphataemic rickets has beneficial effects in terms of growth, improved bone mineralization and reduced bone deformities. However, the Committee considered that hypophosphataemic rickets is a relatively rare condition which constitutes only a small sub-group of all hypophosphataemic conditions that may benefit from phosphorus supplementation. The Committee therefore considered that a comprehensive review of the evidence for phosphorus treatment across all conditions for which it is indicated should be requested for future consideration.

